ENVB · Enveric Biosciences, Inc. · Debt
$1.52
+0.03 (+2.01%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.80M
Shares
4.48M
Volume · Nov 12
32.25K
Avg daily vol (3M)
71.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2023-06-30 | USD 9,611 | 10-Q filed 2023-08-11 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
890821
CUSIP
29405E505
13F (30d)
16 filings
12 filers
Visit website
Investor relations